4.6 Article

Tau levels are higher in objective subtle cognitive decline but not subjective memory complaint

期刊

ALZHEIMERS RESEARCH & THERAPY
卷 14, 期 1, 页码 -

出版社

BMC
DOI: 10.1186/s13195-022-01060-1

关键词

Subjective memory concern; Subjective memory complaints; Subtle cognitive decline; Neuropsychology; Tau PET; Biomarkers; Preclinical Alzheimer's disease

资金

  1. US Department of Veterans Affairs Clinical Sciences Research and Development Service [1IK2CX001865, 1I01CX001842, 1IK2CX001415]
  2. NIH/NIA [P30 AG062429, R03 AG070435, R01 AG063782, R01 AG049810, R01 AG054049]
  3. Alzheimer's Association [AARF-17-528918, AARG-18-566254, AARG-17-500358]
  4. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]
  5. DOD ADNI (Department of Defense) [W81XWH-12-2-0012]
  6. National Institute on Aging
  7. National Institute of Biomedical Imaging and Bioengineering
  8. AbbVie
  9. Alzheimer's Association
  10. Alzheimer's Drug Discovery Foundation
  11. Araclon Biotech
  12. BioClinica, Inc.
  13. Biogen
  14. Bristol-Myers Squibb Company
  15. CereSpir, Inc.
  16. Cogstate
  17. Eisai Inc.
  18. Elan Pharmaceuticals, Inc.
  19. Eli Lilly and Company
  20. EuroImmun
  21. F. Hoffmann-La Roche Ltd. and its affiliated company Genentech, Inc.
  22. Fujirebio
  23. GE Healthcare
  24. IXICO Ltd.
  25. Janssen Alzheimer Immunotherapy Research & Development, LLC.
  26. Johnson & Johnson Pharmaceutical Research & Development LLC.
  27. Lumosity
  28. Lundbeck
  29. Merck Co., Inc.
  30. Meso Scale Diagnostics, LLC.
  31. NeuroRx Research
  32. Neurotrack Technologies
  33. Novartis Pharmaceuticals Corporation
  34. Pfizer Inc.
  35. Piramal Imaging
  36. Servier
  37. Takeda Pharmaceutical Company
  38. Transition Therapeutics
  39. Canadian Institutes of Health Research

向作者/读者索取更多资源

This study examines differences in tau PET levels between individuals with subjective memory complaint (SMC) and objective subtle cognitive decline (Obj-SCD). The results show that Obj-SCD+ participants had higher tau levels and rates of tau positivity compared to Obj-SCD- participants, while SMC groups did not differ in tau levels. Additionally, there was very little agreement between SMC and Obj-SCD classifications.
Background The 2018 NIA-AA Alzheimer's Disease (AD) Research Framework states that subtle cognitive decline in cognitively unimpaired individuals can be measured by subjective reports or evidence of objective decline on neuropsychological measures. Both subjective memory complaint (SMC) and objective subtle cognitive decline (Obj-SCD) have been shown to be associated with future cognitive decline and AD biomarkers. We examined whether there are differences in tau PET levels between (a) SMC- vs. SMC+ participants, (b) Obj-SCD- vs. Obj-SCD+ participants, and (c) participants with overlapping vs. discrepant SMC and Obj-SCD classifications. Methods Cognitively unimpaired participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI; n = 236) were classified at baseline as positive or negative for SMC (SMC- n = 77; SMC+ n = 159) based on the first 12 items of the Cognitive Change Index and/or classified as positive or negative for Obj-SCD (Obj-SCD- n = 173; Obj-SCD+ n = 63) based on previously defined neuropsychological criteria. Analyses of covariance, adjusting for age, sex, APOE epsilon 4 carrier status, and pulse pressure, examined the group differences in tau PET (AV-1451) using a composite standardized uptake variable ratio (SUVR) for regions consistent with Braak stage III/IV. The chi-squared tests examined the tau positivity rates across the groups. Results Obj-SCD+ participants had higher tau continuous SUVR levels (p = .035, eta(2)(p) = .019) and higher rates of tau positivity (15.8% Obj-SCD- vs. 30.2% Obj-SCD+) than Obj-SCD- participants. Neither tau levels (p = .381, eta(2)(p) = .003) nor rates of tau positivity (18.2% SMC- and 20.1% SMC+) differed between the SMC groups. There was very little agreement between SMC and Obj-SCD classifications (42%; kappa = 0.008, p = .862). Participants who were Obj-SCD+ without SMC had the highest tau PET levels and differed from participants who were SMC+ without Obj-SCD (p = .022). Tau levels in participants with both SMC and Obj-SCD did not differ from those with only Obj-SCD (p = .216). Tau positivity rates across the SMC-/Obj-SCD-, SMC+/Obj-SCD-, SMC-/Obj-SCD+, and SMC+/Obj-SCD+ groups were 10.5%, 18.1%, 40.0%, and 25.6%, respectively. Conclusion Participants with Obj-SCD had a greater tau PET burden than those without Obj-SCD, but SMC was not associated with higher tau levels. The combination of SMC and Obj-SCD did not have higher tau levels than Obj-SCD alone. Findings add to the evidence that the Obj-SCD classification is associated with AD biomarkers and faster cognitive decline in ADNI participants, but further work is needed to validate this approach in more representative/diverse cohorts.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据